scan0109 - MistNews · 2021. 1. 6. · ibnsinapharma 30 01000852771 44891137...

5

Transcript of scan0109 - MistNews · 2021. 1. 6. · ibnsinapharma 30 01000852771 44891137...

Page 1: scan0109 - MistNews · 2021. 1. 6. · ibnsinapharma 30 01000852771 44891137 Mohamed.shawky@ibnsina- pharma.com 15/12 3/2 Mohamed.shawky@ibnsina-pharma.com : 0/0 5 Il Head Office
Page 2: scan0109 - MistNews · 2021. 1. 6. · ibnsinapharma 30 01000852771 44891137 Mohamed.shawky@ibnsina- pharma.com 15/12 3/2 Mohamed.shawky@ibnsina-pharma.com : 0/0 5 Il Head Office
Page 3: scan0109 - MistNews · 2021. 1. 6. · ibnsinapharma 30 01000852771 44891137 Mohamed.shawky@ibnsina- pharma.com 15/12 3/2 Mohamed.shawky@ibnsina-pharma.com : 0/0 5 Il Head Office
Page 4: scan0109 - MistNews · 2021. 1. 6. · ibnsinapharma 30 01000852771 44891137 Mohamed.shawky@ibnsina- pharma.com 15/12 3/2 Mohamed.shawky@ibnsina-pharma.com : 0/0 5 Il Head Office
Page 5: scan0109 - MistNews · 2021. 1. 6. · ibnsinapharma 30 01000852771 44891137 Mohamed.shawky@ibnsina- pharma.com 15/12 3/2 Mohamed.shawky@ibnsina-pharma.com : 0/0 5 Il Head Office

Netnography: A Useful Market Research Tool for ...consulting-for-pharma.com/.../pharma_netnography_cfp_part2.pdf · Does netnography support the success of my medicinal product? 4.

Netnography: A Useful Market Research Tool for ...consulting-for-pharma.com/.../pharma_netnography_cfp_part2.pdf · Does netnography support the success of my medicinal product? 4.

INVESTOR PRESENTATION - love-pharma.com

INVESTOR PRESENTATION - love-pharma.com

Ibnsina Pharma Releases Audited 9M18 Results · Mohamed Shawky Investor Relations Manager Email: mohamed.shawky@ibnsina-pharma.com Shareholding Structure (Post IPO and Capital Increase)

Ibnsina Pharma Releases Audited 9M18 Results · Mohamed Shawky Investor Relations Manager Email: [email protected] Shareholding Structure (Post IPO and Capital Increase)

Ibnsina Pharma Releases FY2019 Results EGP 16.6 BN EGP 1.4 BN · Gross profit booked EGP 1.4 billion, up 28.0% year- ... retail pharmaceutical market registeredtotal sales of EGP

Ibnsina Pharma Releases FY2019 Results EGP 16.6 BN EGP 1.4 BN · Gross profit booked EGP 1.4 billion, up 28.0% year- ... retail pharmaceutical market registeredtotal sales of EGP

Investor Presentation · …with a proven track record of success… Market Share 7.0% Established in 2001 under the name “Ibnsina Laborex” in partnership with Pinault Printemps

Investor Presentation · …with a proven track record of success… Market Share 7.0% Established in 2001 under the name “Ibnsina Laborex” in partnership with Pinault Printemps

Effects of IL-21, KIR Blockade, and CD137 Agonism on the ...innate-pharma.com/sites/default/files/ash2014_preclinical_poster... · ———Through direct activation and engagement

Effects of IL-21, KIR Blockade, and CD137 Agonism on the ...innate-pharma.com/sites/default/files/ash2014_preclinical_poster... · ———Through direct activation and engagement

ISP ER 1Q19 - E - Final · Established in 2001, Ibnsina Pharma “ISP” is the fastest growing, and 2nd largest, pharmaceutical distributor in Egypt with a market share of 19.7%

ISP ER 1Q19 - E - Final · Established in 2001, Ibnsina Pharma “ISP” is the fastest growing, and 2nd largest, pharmaceutical distributor in Egypt with a market share of 19.7%

scan0099 - MistNews · 2020. 7. 13. · ibnsinapharma 01000852771 44891137 Mohamed.shawky@ibnsina- pharma.com 15/12 3/2 Mohamed.shawky@ibnsina-pharma.com 0/0 5 THE EUROPEAN BANK FOR

scan0099 - MistNews · 2020. 7. 13. · ibnsinapharma 01000852771 44891137 Mohamed.shawky@ibnsina- pharma.com 15/12 3/2 [email protected] 0/0 5 THE EUROPEAN BANK FOR

Corporate Presentation January 2017 - sensorion-pharma.com · Latest development in the histaminergic pathway applied to vertigo treatment – First-in-class Histamine H4 Receptor

Corporate Presentation January 2017 - sensorion-pharma.com · Latest development in the histaminergic pathway applied to vertigo treatment – First-in-class Histamine H4 Receptor

Peptic ulcer disease - suli-pharma.com

Peptic ulcer disease - suli-pharma.com

COMPANY PROFILE EXCELLENT - Pharmaexcellent-pharma.com/wp-content/uploads/2016/11/Company-Profile.pdfleading companies through various agreements, partnerships and joint ventures,

COMPANY PROFILE EXCELLENT - Pharmaexcellent-pharma.com/wp-content/uploads/2016/11/Company-Profile.pdfleading companies through various agreements, partnerships and joint ventures,

Ibnsina Pharma Releases 9M2019 Results · Market Overview According to data published by IMS Health, Egypt’s retail pharmaceutical market recorded total sales of EGP 55.2 billion

Ibnsina Pharma Releases 9M2019 Results · Market Overview According to data published by IMS Health, Egypt’s retail pharmaceutical market recorded total sales of EGP 55.2 billion

calyx-pharma.comcalyx-pharma.com/Annexure 1_Calyx Chemicals and Pharmaceuticals... · Process for Corporate Person) Regulations, 2016, ... Security for WCL - LC/ LCBD/ LOC First hypothecation

calyx-pharma.comcalyx-pharma.com/Annexure 1_Calyx Chemicals and Pharmaceuticals... · Process for Corporate Person) Regulations, 2016, ... Security for WCL - LC/ LCBD/ LOC First hypothecation

LEO80185-G23 Clinical Study Report 11-Oct-2011leo-pharma.com/Files/Filer/LEO_corporate_downloads/Clinical trial... · 11.4.1.1 Primary Endpoint – Controlled Disease According to

LEO80185-G23 Clinical Study Report 11-Oct-2011leo-pharma.com/Files/Filer/LEO_corporate_downloads/Clinical trial... · 11.4.1.1 Primary Endpoint – Controlled Disease According to

Sales Force Effectiveness - Channel Optimizationchannel-optimization-pharma.com/wp-content/uploads/sites/214/2017/...Sales Force Effectiveness ... ZS Associates Access Monitor™ 2015

Sales Force Effectiveness - Channel Optimizationchannel-optimization-pharma.com/wp-content/uploads/sites/214/2017/...Sales Force Effectiveness ... ZS Associates Access Monitor™ 2015

OIC-VET IbnSina Health Capacity Building Programme ... and Tobacco.pdf · OIC-VET IbnSina Health Capacity Building Programme (IbnSina-HCaB) S ES RIC STATISTICAL ECONOMIC AND SOCIAL

OIC-VET IbnSina Health Capacity Building Programme ... and Tobacco.pdf · OIC-VET IbnSina Health Capacity Building Programme (IbnSina-HCaB) S ES RIC STATISTICAL ECONOMIC AND SOCIAL

Regulatory Affairs - Startseite | GBA Labor · GBA-PHARMA.COM Your Challenges Require Smart Solutions. GBA PHARMA GmbH . Fraunhoferstrasse 11 a, 82152 Martinsried, Germany. Regulatory

Regulatory Affairs - Startseite | GBA Labor · GBA-PHARMA.COM Your Challenges Require Smart Solutions. GBA PHARMA GmbH . Fraunhoferstrasse 11 a, 82152 Martinsried, Germany. Regulatory

5 solutions pour défendre l ... - smart-pharma.com€¦ · Confidentiel Smart Pharma Consulting Introduction Les politiques successives visant à maîtriser l’évolution des dépenses

5 solutions pour défendre l ... - smart-pharma.com€¦ · Confidentiel Smart Pharma Consulting Introduction Les politiques successives visant à maîtriser l’évolution des dépenses

R&D Meeting - ds-pharma.com

R&D Meeting - ds-pharma.com

Identification of Organic compoundssuli-pharma.com/uploads/lectures/Identification.pdf · ignition ; elemental analysis; solubility : PH test and classification tests to identify

Identification of Organic compoundssuli-pharma.com/uploads/lectures/Identification.pdf · ignition ; elemental analysis; solubility : PH test and classification tests to identify